|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results provide the first detailed mechanism of how the AR can differentially alter PCa and BCa metastasis; thus, targeting the newly identified AR-miR-525-5p-SLPI axis may help suppress metastasis.
|
31843555 |
2020 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition.
|
24662746 |
2014 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
We then assessed the effects of androgen on β-catenin in AR-positive and AR-negative bladder cancer cell lines.
|
23447569 |
2013 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We therefore conducted this meta-analysis to assess the clinicopathological impact of the expression of androgen receptor (AR) and estrogen receptors (ERs) in bladder cancer.
|
28362839 |
2017 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It is concluded that suppression of AR expression decreased the production of TGF-β, inhibiting EMT and bladder cancer cell growth in vitro and in vivo, implying that its use might be a potential therapeutic target for the treatment of bladder cancer.
|
24329492 |
2014 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas covered: We summarize and discuss available data suggesting the involvement of AR and its potential downstream targets in the development and progression of bladder cancer.
|
28064545 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given that the androgen receptor (AR) has been discussed as a possible factor in the development and progression of bladder cancer, we investigated the predictive value of AR in stage pT1 NMIBC.
|
28342317 |
2017 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Preclinical models have demonstrated that androgen receptor modulation can influence bladder carcinogenesis with an inverse association observed between serum androgen levels and bladder cancer (BC) incidence.
|
29731413 |
2018 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, overexpression of AR suppressed ENZ-induced autophagy-related genes (LC3-II/I, ATG5, and p-AMPKα) in T24 cells, and CQ exerted synergistic effects with ENZ to suppressed AR-responsive genes expression (KLK2 and KLK3) in bladder cancer.
|
31574376 |
2019 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CAG repeats in the androgen receptor gene are shorter in patients with pulmonary, esophageal or bladder carcinoma and longer in women with uterine leiomyoma.
|
20127024 |
2010 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen Receptor Is Inactivated and Degraded in Bladder Cancer Cells by Phenyl Glucosamine via miR-449a Restoration.
|
29659560 |
2018 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We discuss work demonstrating AR expression in bladder cancer and its role in promoting formation and progression of tumors.
|
26229034 |
2015 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study investigated the functional role of androgen-associated androgen receptor (AR) mediated-eRNA MARC1 (eMARC1) in BCa progression.
|
29964053 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings implicate the involvement of both androgens and the AR in bladder cancer.
|
17406000 |
2007 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Determination of the AR status in cystectomy specimens offers new therapeutic approaches in locally advanced bladder cancer.
|
23330817 |
2013 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
|
31234917 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The correlations of miR-124 with XIST and AR in bladder cancer samples were statistically analyzed.
|
28869948 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies suggest that the androgen receptor (AR) might play important roles in influencing bladder cancer progression, yet its clinical application remains unclear.
|
26264279 |
2015 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thiazolyl blue cell viability assay, flow cytometry, scratch wound-healing assay, transwell invasion assay, real-time polymerase chain reaction, and reporter gene assay were performed in AR-positive (e.g., UMUC3, TCCSUP, and 647V-AR) and AR-negative (e.g., UMUC3-AR-short hairpin RNA [shRNA], TCCSUP-AR-shRNA, 647V) bladder cancer lines treated with dihydrotestosterone and each AR antagonist.
|
27330033 |
2016 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice.
|
26862755 |
2016 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of androgen receptor in cell growth and drug sensitivity was also evaluated in vitro and in vivo in several bladder cancer cell lines.
|
22608749 |
2012 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
We indicate that AR plays an essential role in bladder cancer progression in male patients.
|
31119584 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, androgen-mediated androgen receptor signals have been shown to correlate with the promotion of tumor development and progression, which may clearly explain some sex-specific differences in bladder cancer.
|
28241422 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accordingly, the investigation of lncRNAs is improving our understanding of genitourinary cancers, from development to progression and dissemination. lncRNAs are involved in major oncogenic events in genitourinary malignancies, including androgen receptor (AR) signalling in prostate cancer, hypoxia-inducible factor (HIF) pathway activation in renal cell carcinoma and invasiveness in bladder cancer, as well as multiple other proliferation and survival mechanisms.
|
31110275 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging preclinical evidence suggests the critical role of androgen-mediated androgen receptor (AR) signals in the development of bladder cancer.
|
29119053 |
2017 |